Summary

The IVD raw material market is projected to grow from USD 21.5 billion in 2026 to USD 31.1 billion by 2031, growing at a CAGR of 7.7%. The increasing prevalence of chronic and infectious diseases, the rising demand for early and accurate disease diagnosis, and the expanding adoption of advanced diagnostic technologies. The growing use of molecular diagnostic techniques such as PCR, NGS, FISH, and LAMP is increasing demand for high-quality oligonucleotides, nucleic acids, enzymes, and other specialized raw materials. At the same time, the rapid expansion of point-of-care testing is driving the need for antibodies, antigens, membranes, labels, and detection materials used in rapid diagnostic assays. Furthermore, advancements in recombinant technologies, protein engineering, and assay development are improving the performance, sensitivity, and reliability of diagnostic tests. These innovations are enabling diagnostic manufacturers to develop more accurate and efficient testing solutions, thereby supporting the growth of the global IVD raw material market. The infectious disease testing segment is expected to account for the largest share of the IVD raw material market, by application, during the forecast period. Based on application, the IVD raw material market is segmented into infectious disease testing, oncology/cancer markers, cardiac markers, diabetes & metabolic disorders, autoimmune disease, blood screening, women's health & fertility, genetic & rare disease testing, and others. The infectious disease testing segment accounts for the largest market share due to the high global burden of infectious diseases and the increasing demand for rapid, accurate, and large-scale diagnostic testing. Diagnostic manufacturers extensively use raw materials such as antibodies, antigens, enzymes, oligonucleotides, nucleic acids, and detection reagents to develop immunoassays, molecular diagnostic tests, and point-of-care testing solutions for detecting bacterial, viral, fungal, and parasitic infections. Additionally, growing investments in public health programs, increasing awareness of early disease diagnosis, and the continued adoption of advanced molecular diagnostic technologies are driving demand for high-quality IVD raw materials in infectious disease testing, making it the largest application segment of the market. The immunoassay segment has the largest market share in the IVD raw material market during the forecast period. The global IVD raw material market can be segmented by technology into immunoassay, molecular diagnostics, clinical chemistry, hematology, microbiology & culture, coagulation, point-of-care testing, flow cytometry, and others. Among these, the immunoassay segment accounted for the largest market share. Immunoassay-based diagnostics remain a fundamental component of routine disease testing due to their high sensitivity, specificity, cost-effectiveness, and broad application across infectious diseases, oncology, cardiac markers, autoimmune disorders, and hormone testing. The widespread adoption of immunoassay platforms has generated substantial demand for critical raw materials, including antibodies, antigens, proteins, enzymes, labels, and detection reagents. Furthermore, continuous advancements in assay development, increasing diagnostic testing volumes, growing demand for rapid and accurate diagnostic solutions, and the expansion of automated immunoassay analyzers are expected to support the continued adoption of immunoassay technologies, thereby driving demand for IVD raw materials worldwide. Asia Pacific: The fastest-growing market for IVD raw material from 2026 to 2031 The global IVD raw material market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific is projected to grow at the highest regional CAGR from 2026 to 2031. The region's growth is driven by the increasing prevalence of chronic and infectious diseases, expanding healthcare infrastructure, rising investments in diagnostic technologies, and growing demand for early and accurate disease diagnosis. China is strengthening its domestic diagnostic manufacturing capabilities through healthcare modernization initiatives and increased investment in biotechnology and life sciences. India is witnessing significant growth in diagnostic testing volumes, supported by the expansion of clinical laboratories and molecular diagnostic facilities, as well as the adoption of point-of-care testing. Additionally, Japan's advanced healthcare system, aging population, and strong focus on precision medicine continue to drive demand for high-quality diagnostic assays and the raw materials required for their development. These factors are expected to support the rapid growth of the IVD raw material market across the Asia Pacific region during the forecast period. The break-up of the profile of primary participants in the IVD raw market: ・ By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier - 30% ・ By Designation: C-level Executives - 27%, Directors – 18%, and Others - 55% ・ By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa - 4% Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Medix Biochemica (Finland), Bio-Techne Corporation (U.S.), Fapon Biotech Inc. (China), Meridian Bioscience, Inc. (U.S.), BBI Solutions (U.K.), Toyobo Co., Ltd. (Japan), Roche CustomBiotech (Switzerland), Integrated DNA Technologies, Inc. (U.S.), Cytiva (U.S.), Sartorius AG (Germany), LGC Biosearch Technologies (U.S.), Fitzgerald Industries International (U.S.), and Bangs Laboratories, Inc. (U.S.) are some of the key players operating in the global IVD raw material market. Research Coverage: This research report categorizes the IVD raw material market by product type (antibodies, antigens & proteins, enzymes & substrates, oligonucleotides & nucleic acids, beads & particles, membranes, labels & detection materials, buffers & diluents, and others), by technology (immunoassay, molecular diagnostics, clinical chemistry, hematology, microbiology & culture, coagulation, point-of-care testing, flow cytometry, and others), by application (infectious disease testing, oncology/cancer markers, cardiac markers, diabetes & metabolic disorders, autoimmune disease, blood screening, women's health & fertility, genetic & rare disease testing, and others), by supply source (in-house manufacturing [captive] and third-party supply [merchant]), by source/origin (biological/natural source, recombinant/synthetic, and others), by end user (IVD manufacturers, contract research organizations, academic & research institutes, pharmaceutical & biotech companies, and others), and by region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the IVD raw material market. A detailed analysis of the key industry players has been conducted to provide insights into their business overview, product portfolios, key strategies such as acquisitions, partnerships, collaborations, capacity expansions, and product launches, as well as recent developments associated with the IVD raw material market. Competitive analysis of emerging companies and market participants within the IVD raw materials ecosystem is also covered in this report. Reasons to buy this report: The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall IVD raw material market and the subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: ・ Analysis of key drivers (increasing geriatric population and subsequent rise in chronic diseases, growing awareness of early disease diagnosis in emerging economies, emergence of rapid point-of-care [POC] technologies and rising adoption of automated analyzers, and growing preference for personalized medicine), restraints (unfavorable reimbursement scenario, stringent regulatory requirements), opportunities (introduction of disease-specific biomarkers and tests, increasing significance of companion diagnostics, growth opportunities in developing countries, improvements in immunoassay diagnostic technologies, and the growing digitalization trend), and challenges (maintaining batch-to-batch consistency and quality of raw materials, and supply chain disruptions affecting the availability of critical biological and synthetic reagents) influencing the growth of the IVD raw material market ・ Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the IVD raw material market ・ Market Development: Comprehensive information about lucrative markets—the report analyzes the IVD raw material market across varied regions. ・ Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the IVD raw material market ・ Competitive Assessment: In-depth assessment of market shares, growth strategies, and product portfolios of leading players such as Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Medix Biochemica (Finland), Bio-Techne Corporation (U.S.), and Fapon Biotech Inc. (China), among others

ページTOPに戻る

Table of Contents

1 INTRODUCTION 41
1.1 STUDY OBJECTIVES 41
1.2 MARKET DEFINITION 41
1.3 STUDY SCOPE 42
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 42
1.3.2 INCLUSIONS AND EXCLUSIONS 43
1.3.3 YEARS CONSIDERED 44
1.3.4 CURRENCY CONSIDERED 44
1.4 STAKEHOLDERS 44
2 EXECUTIVE SUMMARY 45
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 45
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 46
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 47
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 48
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 49
3 PREMIUM INSIGHTS 50
3.1 IVD RAW MATERIALS MARKET OVERVIEW 50
3.2 IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2026 VS. 2031 51
3.3 IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2026 VS. 2031 51
3.4 IVD RAW MATERIALS MARKET, BY APPLICATION, 2026 VS. 2031 52
3.5 IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2026 VS. 2031 52
3.6 IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2026 VS. 2031 53
3.7 IVD RAW MATERIALS MARKET, BY END USER, 2026 VS. 2031 53
3.8 IVD RAW MATERIALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54
4 MARKET OVERVIEW 55
4.1 INTRODUCTION 55
4.2 MARKET DYNAMICS 55
4.2.1 DRIVERS 56
4.2.1.1 Rising prevalence of chronic and infectious diseases 56
4.2.1.2 Growing adoption of personalized medicine and companion diagnostics 56
4.2.1.3 Increasing use of recombinant antibodies, proteins, and enzymes 57
4.2.1.4 Growing demand for raw materials supporting decentralized and rapid diagnostics 58
4.2.2 RESTRAINTS 58
4.2.2.1 High validation and quality-control costs 58
4.2.2.2 Long supplier qualification cycles 59
4.2.2.3 Limited availability of specialized biological raw materials 59
4.2.3 OPPORTUNITIES 60
4.2.3.1 Adoption of recombinant and animal-free raw materials 60
4.2.3.2 Localization of raw material manufacturing in emerging markets 60
4.2.3.3 Development of next-generation molecular diagnostic reagents 61
4.2.4 CHALLENGES 62
4.2.4.1 Maintaining batch-to-batch consistency 62
4.2.4.2 Building resilient supply chains for critical biological inputs 62
4.2.4.3 Meeting evolving IVDR/FDA supplier documentation requirements 63
4.3 UNMET NEEDS AND WHITE SPACES 63
4.3.1 UNMET NEEDS IN IVD RAW MATERIALS MARKET 63
4.3.2 WHITE SPACE OPPORTUNITIES 64
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 65
4.4.1 INTERCONNECTED MARKETS 65
4.4.2 CROSS-SECTOR OPPORTUNITIES 65
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 66
4.5.1 KEY MOVES AND STRATEGIC FOCUS 66
5 INDUSTRY TRENDS 68
5.1 PORTER’S FIVE FORCES ANALYSIS 68
5.1.1 THREAT OF NEW ENTRANTS 69
5.1.2 THREAT OF SUBSTITUTES 69
5.1.3 BARGAINING POWER OF SUPPLIERS 69
5.1.4 BARGAINING POWER OF BUYERS 70
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 70
5.2 MACROECONOMIC INDICATORS 70
5.2.1 INTRODUCTION 70
5.2.2 GDP TRENDS AND FORECAST 70
5.3 SUPPLY CHAIN ANALYSIS 72
5.4 VALUE CHAIN ANALYSIS 73
5.5 ECOSYSTEM ANALYSIS 75
5.6 PRICING ANALYSIS 76
5.6.1 AVERAGE SELLING PRICE, BY REGION, 2024–2026 76
5.6.2 AVERAGE SELLING PRICE, BY KEY PLAYER, 2024–2026 77
5.7 TRADE ANALYSIS 78
5.7.1 IMPORT SCENARIO (HS CODE 300213) 78
5.7.2 EXPORT SCENARIO (HS CODE 300213) 78
5.8 KEY CONFERENCES & EVENTS, 2026–2027 79
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 79
5.10 INVESTMENT & FUNDING SCENARIO 80
5.11 IMPACT OF US TARIFFS—IVD RAW MATERIALS MARKET 81
5.11.1 INTRODUCTION 81
5.11.2 KEY TARIFF RATES 81
5.11.3 PRICE IMPACT ANALYSIS 82
5.11.4 IMPACT ON REGIONS 82
5.11.4.1 North America 82
5.11.4.2 Europe 82
5.11.4.3 Asia Pacific 83
5.11.5 IMPACT ON END-USE INDUSTRIES 83
5.11.5.1 OEM IVD manufacturers 83
5.11.5.2 Biopharmaceutical companies 83
5.11.5.3 CROs and research institutions 83
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 84
6.1 KEY EMERGING TECHNOLOGIES 84
6.1.1 IMMUNOASSAY 84
6.2 COMPLEMENTARY TECHNOLOGIES 84
6.2.1 MOLECULAR DIAGNOSTICS 84
6.3 TECHNOLOGY/PRODUCT ROADMAP 85
6.4 PATENT ANALYSIS 87
6.4.1 LIST OF KEY PATENTS 88
6.5 FUTURE APPLICATIONS 88
6.6 IMPACT OF AI/GENERATIVE AI ON IVD RAW MATERIALS MARKET 89
6.6.1 INTRODUCTION 89
6.6.2 TOP USE CASES AND MARKET POTENTIAL 90
6.6.3 KEY COMPANIES IMPLEMENTING AI 90
6.6.4 FUTURE OF AI 91
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 92
7.1 REGIONAL REGULATIONS AND COMPLIANCE 92
7.1.1 REGULATORY LANDSCAPE 92
7.1.1.1 North America 92
7.1.1.1.1 US 92
7.1.1.1.2 Canada 93
7.1.1.2 Europe 94
7.1.1.3 Asia Pacific 94
7.1.1.3.1 Japan 95
7.1.1.3.2 China 95
7.1.1.3.3 India 96
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
7.1.2.1 North America 97
7.1.2.2 Europe 97
7.1.2.3 Asia Pacific 97
7.1.2.4 Latin America 98
7.1.2.5 Middle East & Africa 98
7.2 SUSTAINABILITY INITIATIVES 98
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN
IVD RAW MATERIALS MARKET 98
7.2.1.1 Eco-friendly Initiatives 99
7.2.2 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 100
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 101
8.1 DECISION-MAKING PROCESS 101
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 101
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 101
8.2.2 BUYING CRITERIA 102
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 103
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 104
8.5 MARKET PROFITABILITY 104
8.5.1 REVENUE POTENTIAL 105
8.5.2 COST DYNAMICS 105
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 105
9 IVD RAW MATERIALS MARKET, BY PRODUCT TYPE 106
9.1 INTRODUCTION 107
9.2 ANTIBODIES 107
9.2.1 MONOCLONAL ANTIBODIES 110
9.2.1.1 Increasing demand for highly specific and reproducible antibody reagents in immunoassay and rapid diagnostic applications to drive segment growth 110
9.2.2 POLYCLONAL ANTIBODIES 112
9.2.2.1 Broad target recognition and strong signal generation to sustain demand for polyclonal antibodies in diagnostic assays 112
9.2.3 RECOMBINANT ANTIBODIES 114
9.2.3.1 Growing adoption of engineered antibodies to improve consistency, scalability, and performance of IVD assays 114
9.3 ANTIGENS & PROTEINS 115
9.3.1 RECOMBINANT ANTIGENS 117
9.3.1.1 Growing preference for scalable and consistent antigen production to support increasing IVD assay demand 117
9.3.2 NATIVE PROTEINS 119
9.3.2.1 Continued demand for biologically authentic proteins in sensitive assay development and clinically representative IVD applications 119
9.3.3 CALIBRATORS & STANDARDS 121
9.3.3.1 Increasing emphasis on assay standardization and traceability to drive demand for calibrators & reference materials 121
9.4 ENZYMES & SUBSTRATES 122
9.4.1 DETECTION ENZYMES 125
9.4.1.1 Increasing adoption of enzyme-based signal generation to improve sensitivity and quantitative performance of immunoassays 125
9.4.2 AMPLIFICATION ENZYMES 126
9.4.2.1 Growing adoption of molecular diagnostic testing to accelerate demand for high-performance amplification enzymes 126
9.4.3 SUBSTRATES & COENZYMES 128
9.4.3.1 Increasing need for optimized reaction components to enhance enzyme activity and diagnostic assay signal generation 128
9.5 OLIGONUCLEOTIDES & NUCLEIC ACIDS 130
9.5.1 PRIMERS & PROBES 132
9.5.1.1 Increasing adoption of PCR and multiplex molecular assays to drive demand for sequence-specific primers and probes 132
9.5.2 SYNTHETIC DNA/RNA 134
9.5.2.1 Growing use of synthetic DNA and RNA sequences to accelerate molecular assay development and validation 134
9.6 BEADS & PARTICLES 135
9.6.1 MAGNETIC BEADS 137
9.6.1.1 Growing adoption of automated magnetic-particle immunoassays to drive demand for high-performance magnetic beads 137
9.6.2 LATEX BEADS 139
9.6.2.1 Widespread use of latex particle-based agglutination and turbidimetric assays to sustain demand for latex beads 139
9.6.3 GOLD NANOPARTICLES 141
9.6.3.1 Increasing adoption of gold nanoparticle-based signal generation in rapid and visually readable diagnostic assays 141
9.7 MEMBRANES 142
9.7.1 NITROCELLULOSE MEMBRANES 144
9.7.1.1 High protein-binding capacity and controlled capillary flow to underpin nitrocellulose use across lateral flow and membrane-based immunodiagnostics 144
9.7.2 NYLON & PVDF MEMBRANES 146
9.7.2.1 Higher chemical resistance and specialized biomolecule immobilization requirements to sustain demand 146
9.7.3 GLASS FIBER PADS 148
9.7.3.1 Consistent sample and conjugate transport to strengthen role of glass fiber pads in lateral flow test construction 148
9.8 LABELS & DETECTION MATERIALS 150
9.8.1 FLUORESCENT DYES 152
9.8.1.1 Higher analytical sensitivity and instrument-based quantification to expand use of fluorescent detection in IVD 152
9.8.2 CHEMILUMINESCENT LABELS 154
9.8.2.1 Demand for ultra-sensitive immunoassays to sustain adoption of chemiluminescent labels 154
9.8.3 COLLOIDAL GOLD CONJUGATES 156
9.8.3.1 Established visual-readout capability and simplicity of lateral flow testing to sustain demand for colloidal gold conjugates 156
9.9 BUFFERS & DILUENTS 158
9.9.1 GREATER EMPHASIS ON REACTION STABILITY AND INTERFERENCE CONTROL TO SUPPORT RELIABLE IVD ASSAY PERFORMANCE 158
9.10 OTHER PRODUCTS 160
10 IVD RAW MATERIALS MARKET, BY TECHNOLOGY 163
10.1 INTRODUCTION 164
10.2 IMMUNOASSAY 164
10.2.1 INCREASING ADOPTION OF HIGH-SENSITIVITY, AUTOMATED IMMUNOASSAYS TO SUSTAIN DEMAND FOR RAW MATERIALS 164
10.3 MOLECULAR DIAGNOSTICS 166
10.3.1 EXPANSION OF PCR AND ISOTHERMAL AMPLIFICATION FORMATS TO INCREASE DEMAND FOR ENGINEERED POLYMERASES, MASTER MIXES, OLIGONUCLEOTIDES, AND NUCLEIC ACID CONTROLS 166
10.4 CLINICAL CHEMISTRY 168
10.4.1 INCREASING DEMAND FOR HIGH-QUALITY ENZYMES, PROTEINS, LIPOPROTEINS, AND REFERENCE MATERIALS TO SUPPORT AUTOMATED QUANTITATIVE TESTING 168
10.5 HEMATOLOGY 170
10.5.1 GROWING DEMAND FOR CELL-BASED REFERENCE MATERIALS AND BLOOD-DERIVED COMPONENTS TO STRENGTHEN RAW-MATERIAL REQUIREMENTS FOR HEMATOLOGY DIAGNOSTICS 170
10.6 MICROBIOLOGY & CULTURE 172
10.6.1 ADVANCES IN CULTURE-MEDIA FORMULATION AND MICROBIAL IDENTIFICATION TO STRENGTHEN DEMAND FOR SPECIALIZED MICROBIOLOGY RAW MATERIALS 172
10.7 COAGULATION TESTING 174
10.7.1 GREATER EMPHASIS ON FAST, STANDARDIZED MEASUREMENT OF CLOTTING AND FIBRINOLYSIS TO SHAPE RAW MATERIAL REQUIREMENTS IN COAGULATION DIAGNOSTICS 174
10.8 FLOW CYTOMETRY 176
10.8.1 MULTIPARAMETER CELLULAR ANALYSIS TO INCREASE DEMAND FOR HIGHLY SPECIFIC ANTIBODIES AND FLUORESCENT DETECTION MATERIALS 176
10.9 OTHER TECHNOLOGIES 178
11 IVD RAW MATERIALS MARKET, BY APPLICATION 181
11.1 INTRODUCTION 182
11.2 INFECTIOUS DISEASES 182
11.2.1 BROAD PATHOGEN COVERAGE AND FREQUENT DEMAND FOR RAPID, SENSITIVE TESTING TO DRIVE MARKET GROWTH 182
11.3 ONCOLOGY/CANCER MARKERS 184
11.3.1 MOLECULAR EXPANSION OF BIOMARKER-BASED CANCER DETECTION AND MONITORING TO INCREASE DEMAND FOR RAW MATERIALS 184
11.4 CARDIAC MARKERS 186
11.4.1 HIGH DISEASE PREVALENCE AND USE OF HIGH-SENSITIVITY BIOMARKERS TO STRENGTHEN DEMAND FOR CARDIAC-MARKER RAW MATERIALS 186
11.5 DIABETES & METABOLIC DISORDERS 188
11.5.1 EXPANDING BIOMARKER-BASED SCREENING TO SUSTAIN DEMAND FOR HBA1C, INSULIN, GLUCOSE, AND RELATED IVD RAW MATERIALS 188
11.6 AUTOIMMUNE DISEASES 190
11.6.1 GROWING RELIANCE ON AUTOANTIBODY-BASED TESTING TO SUPPORT DIAGNOSIS OF DIVERSE AUTOIMMUNE CONDITIONS AND EXPAND DEMAND FOR HIGHLY SPECIFIC IVD RAW MATERIALS 190
11.7 BLOOD SCREENING 192
11.7.1 MANDATORY SCREENING OF DONATED BLOOD AND NEED TO DETECT MULTIPLE TRANSFUSION-TRANSMISSIBLE INFECTIONS UNDERPIN DEMAND FOR DIVERSE IVD RAW MATERIALS 192
11.8 WOMEN’S HEALTH & FERTILITY 194
11.8.1 HIGH PREVALENCE OF INFERTILITY AND EXPANDING HORMONE-BASED REPRODUCTIVE TESTING TO SUSTAIN THE DEMAND 194
11.9 GENETIC & RARE DISEASE TESTING 196
11.9.1 EXPANSION OF MOLECULAR AND GENETIC TESTING TO ADDRESS A LARGE AND CLINICALLY DIVERSE POPULATION 196
11.10 OTHER APPLICATIONS 198
12 IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE 201
12.1 INTRODUCTION 202
12.2 IN-HOUSE MANUFACTURING 202
12.2.1 GREATER CONTROL OVER CRITICAL REAGENTS AND ASSAY PERFORMANCE TO SUSTAIN IN-HOUSE PRODUCTION 202
12.3 THIRD-PARTY SUPPLY 204
12.3.1 OUTSOURCING SPECIALIZED CAPABILITIES TO IMPROVE FLEXIBILITY AND ACCELERATE IVD DEVELOPMENT 204
13 IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN 207
13.1 INTRODUCTION 208
13.2 BIOLOGICAL/NATURAL SOURCES 208
13.2.1 ANIMAL-DERIVED 210
13.2.1.1 Established assay performance and broad availability to sustain use of animal-derived IVD raw materials 210
13.2.2 HUMAN-DERIVED 212
13.2.2.1 Clinical relevance and patient-like matrices to sustain demand for human-derived IVD raw materials 212
13.3 RECOMBINANT/SYNTHETIC SOURCES 214
13.3.1 E. COLI-EXPRESSED 217
13.3.1.1 Scalable production and strong suitability for non-glycosylated proteins to support E. coli-based recombinant IVD materials 217
13.3.2 CHO-EXPRESSED 219
13.3.2.1 Mammalian expression for structurally complex biomarkers to improve assay relevance and performance 219
13.3.3 CHEMICALLY SYNTHESIZED 221
13.3.3.1 Precisely defined composition and scalable manufacturing to expand the role of synthetic materials in IVD 221
13.4 OTHER SOURCES 223
14 IVD RAW MATERIALS MARKET, BY END USER 225
14.1 INTRODUCTION 226
14.2 IVD MANUFACTURERS 226
14.2.1 EXPANDING ASSAY PORTFOLIOS AND TIGHTER CONTROL OF CRITICAL COMPONENTS TO DRIVE RAW-MATERIAL CONSUMPTION 226
14.3 CONTRACT RESEARCH ORGANIZATIONS 228
14.3.1 INCREASING OUTSOURCING OF ASSAY DEVELOPMENT AND VALIDATION TO ACCELERATE IVD COMMERCIALIZATION 228
14.4 ACADEMIC & RESEARCH INSTITUTES 230
14.4.1 GROWING TRANSLATIONAL RESEARCH AND ASSAY DEVELOPMENT TO EXPAND CONSUMPTION OF SPECIALIZED IVD RAW MATERIALS 230
14.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 232
14.5.1 INTEGRATION OF DIAGNOSTICS INTO DRUG DEVELOPMENT TO INCREASE DEMAND FOR BIOMARKER AND ASSAY COMPONENTS 232
14.6 OTHER END USERS 234
15 IVD RAW MATERIALS MARKET, BY REGION 237
15.1 INTRODUCTION 238
15.2 NORTH AMERICA 238
15.2.1 US 246
15.2.1.1 Increasing demand for advanced diagnostics and a mature reimbursement framework to drive market 246
15.2.2 CANADA 252
15.2.2.1 Rising disease prevalence and demand for early diagnoses drive market growth 252
15.3 EUROPE 259
15.3.1 GERMANY 266
15.3.1.1 Increasing investments in life sciences and advanced diagnostics to propel demand for IVD raw materials 266
15.3.2 UK 273
15.3.2.1 Rising adoption of genomic testing and advanced diagnostics to support demand growth 273
15.3.3 FRANCE 280
15.3.3.1 High healthcare expenditure and continued investment in genomic medicine to drive market 280
15.3.4 ITALY 287
15.3.4.1 Growing geriatric population and increasing burden of chronic diseases to boost demand for IVD raw materials 287
15.3.5 SPAIN 294
15.3.5.1 Increasing adoption of genomic testing and advanced diagnostics to support the market 294
15.3.6 REST OF EUROPE 301
15.4 ASIA PACIFIC 307
15.4.1 CHINA 315
15.4.1.1 Growing focus on preventive care and localization of IVD raw materials to boost market 315
15.4.2 JAPAN 321
15.4.2.1 Increasing research investment and adoption of advanced diagnostics to support market growth 321
15.4.3 INDIA 328
15.4.3.1 Rising incidence of diabetes and cancer and increasing localization of IVD manufacturing to augment growth 328
15.4.4 REST OF ASIA PACIFIC 334
15.5 LATIN AMERICA 341
15.5.1 INCREASING HEALTHCARE INVESTMENT, DISEASE BURDEN, AND EXPANSION OF DIAGNOSTIC ACCESS TO SUPPORT MARKET GROWTH 341
15.6 MIDDLE EAST & AFRICA 347
15.6.1 INCREASING HEALTHCARE INVESTMENT, PREVENTIVE SCREENING, AND DIAGNOSTIC INFRASTRUCTURE TO SUPPORT MARKET GROWTH 347
16 IVD RAW MATERIALS MARKET: VOLUME ANALYSIS 355
16.1 INTRODUCTION 355
16.2 GLOBAL: NAT BASED PCR EQUIPMENT SOLD, 2024–2031 (THOUSAND UNITS) 355
17 COMPETITIVE LANDSCAPE 356
17.1 INTRODUCTION 356
17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 356
17.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN IVD RAW MATERIALS MARKET 356
17.3 REVENUE ANALYSIS, 2023–2025 357
17.4 MARKET SHARE ANALYSIS, 2025 358
17.4.1 THIRD-PARTY SUPPLIERS MARKET SHARE ANALYSIS, 2025 358
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 360
17.5.1 STARS 360
17.5.2 EMERGING LEADERS 360
17.5.3 PERVASIVE PLAYERS 360
17.5.4 PARTICIPANTS 360
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 362
17.5.5.1 Company footprint 362
17.5.5.2 Region footprint 362
17.5.5.3 Product type footprint 363
17.5.5.4 End-user footprint 364
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 364
17.6.1 PROGRESSIVE COMPANIES 364
17.6.2 RESPONSIVE COMPANIES 364
17.6.3 DYNAMIC COMPANIES 365
17.6.4 STARTING BLOCKS 365
17.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 366
17.6.5.1 Detailed list of key startups/SMEs 366
17.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 366
17.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 367
17.7 COMPANY VALUATION & FINANCIAL METRICS 367
17.7.1 FINANCIAL METRICS 367
17.7.2 COMPANY VALUATION 368
17.8 BRAND/PRODUCT COMPARISON 369
17.9 COMPETITIVE SCENARIO 370
17.9.1 PRODUCT LAUNCHES & APPROVALS 370
17.9.2 DEALS 370
18 COMPANY PROFILES 372
18.1 KEY PLAYERS 372
18.1.1 MERCK KGAA 372
18.1.1.1 Business overview 372
18.1.1.2 Products offered 373
18.1.1.3 Recent developments 380
18.1.1.3.1 Product launches & approvals 380
18.1.1.3.2 Deals 380
18.1.1.4 MnM view 380
18.1.1.4.1 Key strengths 380
18.1.1.4.2 Strategic choices 380
18.1.1.4.3 Weaknesses and competitive threats 381
18.1.2 THERMO FISHER SCIENTIFIC 382
18.1.2.1 Business overview 382
18.1.2.2 Products offered 383
18.1.2.3 Recent developments 389
18.1.2.3.1 Product enhancements 389
18.1.2.3.2 Deals 389
18.1.2.4 MnM view 389
18.1.2.4.1 Key strengths 389
18.1.2.4.2 Strategic choices 390
18.1.2.4.3 Weaknesses & competitive threats 390
18.1.3 BIO-TECHNE CORPORATION 391
18.1.3.1 Business overview 391
18.1.3.2 Products & services offered 392
18.1.3.3 Recent developments 399
18.1.3.3.1 Product launches & approvals 399
18.1.3.3.2 Deals 399
18.1.3.4 MnM view 399
18.1.3.4.1 Key strengths 399
18.1.3.4.2 Strategic choices 399
18.1.3.4.3 Weaknesses & competitive threats 400
18.1.4 FAPON BIOTECH 401
18.1.4.1 Business overview 401
18.1.4.2 Products & services offered 402
18.1.4.3 Recent developments 407
18.1.4.3.1 Product launches & approvals 407
18.1.4.4 MnM view 407
18.1.4.4.1 Key strengths 407
18.1.4.4.2 Strategic choices 407
18.1.4.4.3 Weaknesses & competitive threats 407
18.1.5 MERIDIAN BIOSCIENCE 408
18.1.5.1 Business overview 408
18.1.5.2 Products offered 409
18.1.5.3 Recent developments 415
18.1.5.3.1 Product launches 415
18.1.5.3.2 Deals 415
18.1.5.4 MnM view 415
18.1.5.4.1 Key strengths 415
18.1.5.4.2 Strategic choices 415
18.1.5.4.3 Weaknesses & competitive threats 415
18.1.6 MEDIX BIOCHEMICA 416
18.1.6.1 Business overview 416
18.1.6.2 Products & services offered 417
18.1.6.3 Recent developments 422
18.1.6.3.1 Deals 422
18.1.6.3.2 Expansions 423
18.1.7 ROCHE CUSTOMBIOTECH 424
18.1.7.1 Business overview 424
18.1.7.2 Products & services offered 425
18.1.8 DANAHER CORPORATION 431
18.1.8.1 Business overview 431
18.1.8.2 Products & services offered 432
18.1.8.3 Recent developments 440
18.1.8.3.1 Deals 440
18.1.9 SARTORIUS AG 441
18.1.9.1 Business overview 441
18.1.9.2 Products offered 442
18.1.10 HYTEST LTD. 445
18.1.10.1 Business overview 445
18.1.10.2 Products offered 445
18.1.11 TOYOBO CO., LTD. 453
18.1.11.1 Business overview 453
18.1.11.2 Products offered 454
18.1.12 LGC BIOSEARCH TECHNOLOGIES 460
18.1.12.1 Business overview 460
18.1.12.2 Products offered 461
18.2 OTHER PLAYERS 466
18.2.1 BBI SOLUTIONS 466
18.2.2 SURMODICS IVD 467
18.2.3 AHLSTROM OYJ 468
18.2.4 BANGS LABORATORIES 469
18.2.5 SCRIPPS LABORATORIES, INC. 470
18.2.6 MIKROGEN GMBH 471
18.2.7 ADVANCED MICRODEVICES PVT. LTD. 472
18.2.8 SEKISUI DIAGNOSTICS 473
18.2.9 RANDOX LABORATORIES LTD. 474
18.2.10 HIMEDIA LABORATORIES 475
18.2.11 SINO BIOLOGICAL 476
18.2.12 BIOSYNTH 477
18.2.13 NEW ENGLAND BIOLABS, INC. 478
19 RESEARCH METHODOLOGY 479
19.1 RESEARCH DATA 479
19.2 SECONDARY DATA 480
19.2.1 LIST OF SECONDARY SOURCES 480
19.2.2 PRIMARY DATA 481
19.2.2.1 Key data from primary sources 482
19.2.2.2 Breakdown of primary interviews 484
19.3 MARKET SIZE ESTIMATION 484
19.3.1 TOTAL MARKET SIZE: IVD RAW MATERIALS MARKET 485
19.3.2 BOTTOM-UP APPROACH 485
19.3.2.1 Approach 2: Study of annual reports and investor presentations 485
19.3.2.2 Approach 3: Primary interviews 486
19.3.2.3 Growth forecast 486
19.3.3 TOP-DOWN APPROACH 487
19.4 DATA TRIANGULATION 487
19.5 RESEARCH ASSUMPTIONS 488
19.5.1 STUDY-RELATED ASSUMPTIONS 488
19.6 STUDY ASSUMPTIONS 489
19.6.1 GROWTH RATE ASSUMPTIONS 490
19.7 RESEARCH LIMITATIONS 490
19.8 RISK ASSESSMENT 490
20 APPENDIX 491
20.1 DISCUSSION GUIDE 491
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 496
20.3 CUSTOMIZATION OPTIONS 498
20.4 RELATED REPORTS 498
20.5 AUTHOR DETAILS 499

ページTOPに戻る

List of Tables/Graphs

TABLE 1 RECENT INDICATORS SUPPORTING PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS 57.
TABLE 2 RECENT INDUSTRY DEVELOPMENTS SUPPORTING RECOMBINANT BIOMOLECULE ADOPTION 57.
TABLE 3 PORTER’S FIVE FORCES ANALYSIS: IMPACT ANALYSIS 69.
TABLE 4 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 70.
TABLE 5 NORTH AMERICA: MACROECONOMIC INDICATORS 71.
TABLE 6 EUROPE: MACROECONOMIC INDICATORS 71.
TABLE 7 ASIA PACIFIC: MACROECONOMIC INDICATORS 72.
TABLE 8 LATIN AMERICA: MACROECONOMIC INDICATORS 72.
TABLE 9 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 72.
TABLE 10 IVD RAW MATERIALS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 75.
TABLE 11 AVERAGE SELLING PRICE OF IVD RAW MATERIALS, BY REGION, 2024–2026 (USD) 76.
TABLE 12 AVERAGE SELLING PRICE OF IVD RAW MATERIALS, KEY PLAYER, 2024–2026 (USD) 77.
TABLE 13 IMPORT DATA FOR HS CODE 300213-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 78.
TABLE 14 EXPORT DATA FOR HS CODE 300213-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 78.
TABLE 15 IVD RAW MATERIALS MARKET: KEY CONFERENCES AND EVENTS, 2026–2027 79.
TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES 81.
TABLE 17 IVD RAW MATERIALS MARKET—KEY TECHNOLOGIES 84.
TABLE 18 KEY PATENTS IN IVD RAW MATERIALS, 2023–2026 88.
TABLE 19 KEY COMPANIES IMPLEMENTING AI IN IVD RAW MATERIALS MARKET 91.
TABLE 20 US: KEY REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS 93.
TABLE 21 CANADA: KEY REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS 93.
TABLE 22 JAPAN: REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS 95.
TABLE 23 CHINA: REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS 96.
TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97.
TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97.
TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97.
TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98.
TABLE 28 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98.
TABLE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 102.
TABLE 30 KEY BUYING CRITERIA, BY END USER 102.
TABLE 31 ADOPTION BARRIERS & INTERNAL CHALLENGES 103.
TABLE 32 IVD RAW MATERIALS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 104.
TABLE 33 IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 107.
TABLE 34 ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 108.
TABLE 35 ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION) 109.
TABLE 36 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 109.
TABLE 37 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 109.
TABLE 38 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 110.
TABLE 39 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION) 111.
TABLE 40 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 111.
TABLE 41 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 111.
TABLE 42 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 112.
TABLE 43 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION) 112.
TABLE 44 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 113.
TABLE 45 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 113.
TABLE 46 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 113.
TABLE 47 RECOMBINANT ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION) 114.
TABLE 48 NORTH AMERICA: RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 114.
TABLE 49 EUROPE: RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 115.
TABLE 50 ASIA PACIFIC: RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 115.
TABLE 51 ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 116.
TABLE 52 ANTIGENS & PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 116.
TABLE 53 NORTH AMERICA: ANTIGENS & PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 116.
TABLE 54 EUROPE: ANTIGENS & PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 117.
TABLE 55 ASIA PACIFIC: ANTIGENS & PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 117.
TABLE 56 RECOMBINANT ANTIGENS MARKET, BY REGION, 2024–2031 (USD MILLION) 118.
TABLE 57 NORTH AMERICA: RECOMBINANT ANTIGENS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 118.
TABLE 58 EUROPE: RECOMBINANT ANTIGENS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 118.
TABLE 59 ASIA PACIFIC: RECOMBINANT ANTIGENS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119.
TABLE 60 NATIVE PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 119.
TABLE 61 NORTH AMERICA: NATIVE PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 120.
TABLE 62 EUROPE: NATIVE PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 120.
TABLE 63 ASIA PACIFIC: NATIVE PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 120.
TABLE 64 CALIBRATORS & STANDARDS MARKET, BY REGION, 2024–2031 (USD MILLION) 121.
TABLE 65 NORTH AMERICA: CALIBRATORS & STANDARDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 66 EUROPE: CALIBRATORS & STANDARDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 122.
TABLE 67 ASIA PACIFIC: CALIBRATORS & STANDARDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 122.
TABLE 68 ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 123.
TABLE 69 ENZYMES & SUBSTRATES MARKET, BY REGION, 2024–2031 (USD MILLION) 123.
TABLE 70 NORTH AMERICA: ENZYMES & SUBSTRATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 124.
TABLE 71 EUROPE: ENZYMES & SUBSTRATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 124.
TABLE 72 ASIA PACIFIC: ENZYMES & SUBSTRATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 124.
TABLE 73 DETECTION ENZYMES MARKET, BY REGION, 2024–2031 (USD MILLION) 125.
TABLE 74 NORTH AMERICA: DETECTION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125.
TABLE 75 EUROPE: DETECTION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 126.
TABLE 76 ASIA PACIFIC: DETECTION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 126.
TABLE 77 AMPLIFICATION ENZYMES MARKET, BY REGION, 2024–2031 (USD MILLION) 127.
TABLE 78 NORTH AMERICA: AMPLIFICATION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127.
TABLE 79 EUROPE: AMPLIFICATION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 128.
TABLE 80 ASIA PACIFIC: AMPLIFICATION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 128.
TABLE 81 SUBSTRATES & COENZYMES MARKET, BY REGION, 2024–2031 (USD MILLION) 129.
TABLE 82 NORTH AMERICA: SUBSTRATES & COENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129.
TABLE 83 EUROPE: SUBSTRATES & COENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129.
TABLE 84 ASIA PACIFIC: SUBSTRATES & COENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 130.
TABLE 85 OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 130.
TABLE 86 OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY REGION, 2024–2031 (USD MILLION) 131.
TABLE 87 NORTH AMERICA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131.
TABLE 88 EUROPE: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131.
TABLE 89 ASIA PACIFIC: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132.
TABLE 90 PRIMERS & PROBES MARKET, BY REGION, 2024–2031 (USD MILLION) 132.
TABLE 91 NORTH AMERICA: PRIMERS & PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133.
TABLE 92 EUROPE: PRIMERS & PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133.
TABLE 93 ASIA PACIFIC: PRIMERS & PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133.
TABLE 94 SYNTHETIC DNA/RNA MARKET, BY REGION, 2024–2031 (USD MILLION) 134.
TABLE 95 NORTH AMERICA: SYNTHETIC DNA/RNA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 134.
TABLE 96 EUROPE: SYNTHETIC DNA/RNA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135.
TABLE 97 ASIA PACIFIC: SYNTHETIC DNA/RNA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135.
TABLE 98 BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 136.
TABLE 99 BEADS & PARTICLES MARKET, BY REGION, 2024–2031 (USD MILLION) 136.
TABLE 100 NORTH AMERICA: BEADS & PARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136.
TABLE 101 EUROPE: BEADS & PARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137.
TABLE 102 ASIA PACIFIC: BEADS & PARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137.
TABLE 103 MAGNETIC BEADS MARKET, BY REGION, 2024–2031 (USD MILLION) 138.
TABLE 104 NORTH AMERICA: MAGNETIC BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 105 EUROPE: MAGNETIC BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 106 ASIA PACIFIC: MAGNETIC BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139.
TABLE 107 LATEX BEADS MARKET, BY REGION, 2024–2031 (USD MILLION) 139.
TABLE 108 NORTH AMERICA: LATEX BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140.
TABLE 109 EUROPE: LATEX BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140.
TABLE 110 ASIA PACIFIC: LATEX BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140.
TABLE 111 GOLD NANOPARTICLES MARKET, BY REGION, 2024–2031 (USD MILLION) 141.
TABLE 112 NORTH AMERICA: GOLD NANOPARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141.
TABLE 113 EUROPE: GOLD NANOPARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142.
TABLE 114 ASIA PACIFIC: GOLD NANOPARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142.
TABLE 115 MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 143.
TABLE 116 MEMBRANES MARKET, BY REGION, 2024–2031 (USD MILLION) 143.
TABLE 117 NORTH AMERICA: MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143.
TABLE 118 EUROPE: MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144.
TABLE 119 ASIA PACIFIC: MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144.
TABLE 120 NITROCELLULOSE MEMBRANES MARKET, BY REGION, 2024–2031 (USD MILLION) 145.
TABLE 121 NORTH AMERICA: NITROCELLULOSE MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145.
TABLE 122 EUROPE: NITROCELLULOSE MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146.
TABLE 123 ASIA PACIFIC: NITROCELLULOSE MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146.
TABLE 124 NYLON & PVDF MEMBRANES MARKET, BY REGION, 2024–2031 (USD MILLION) 147.
TABLE 125 NORTH AMERICA: NYLON & PVDF MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147.
TABLE 126 EUROPE: NYLON & PVDF MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148.
TABLE 127 ASIA PACIFIC: NYLON & PVDF MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148.
TABLE 128 GLASS FIBER PADS MARKET, BY REGION, 2024–2031 (USD MILLION) 149.
TABLE 129 NORTH AMERICA: GLASS FIBER PADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 149.
TABLE 130 EUROPE: GLASS FIBER PADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 131 ASIA PACIFIC: GLASS FIBER PADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 132 LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 151.
TABLE 133 LABELS & DETECTION MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION) 151.
TABLE 134 NORTH AMERICA: LABELS & DETECTION MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151.
TABLE 135 EUROPE: LABELS & DETECTION MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152.
TABLE 136 ASIA PACIFIC: LABELS & DETECTION MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152.
TABLE 137 FLUORESCENT DYES MARKET, BY REGION, 2024–2031 (USD MILLION) 153.
TABLE 138 NORTH AMERICA: FLUORESCENT DYES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153.
TABLE 139 EUROPE: FLUORESCENT DYES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154.
TABLE 140 ASIA PACIFIC: FLUORESCENT DYES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154.
TABLE 141 CHEMILUMINESCENT LABELS MARKET, BY REGION, 2024–2031 (USD MILLION) 155.
TABLE 142 NORTH AMERICA: CHEMILUMINESCENT LABELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155.
TABLE 143 EUROPE: CHEMILUMINESCENT LABELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156.
TABLE 144 ASIA PACIFIC: CHEMILUMINESCENT LABELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156.
TABLE 145 COLLOIDAL GOLD CONJUGATES MARKET, BY REGION, 2024–2031 (USD MILLION) 157.
TABLE 146 NORTH AMERICA: COLLOIDAL GOLD CONJUGATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 147 EUROPE: COLLOIDAL GOLD CONJUGATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158.
TABLE 148 ASIA PACIFIC: COLLOIDAL GOLD CONJUGATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158.
TABLE 149 BUFFERS & DILUENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 159.
TABLE 150 NORTH AMERICA: BUFFERS & DILUENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159.
TABLE 151 EUROPE: BUFFERS & DILUENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 152 ASIA PACIFIC: BUFFERS & DILUENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 153 IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY REGION, 2024–2031 (USD MILLION) 161.
TABLE 154 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 161.
TABLE 155 EUROPE: IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 162.
TABLE 156 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 162.
TABLE 157 IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 164.
TABLE 158 IMMUNOASSAY MARKET, BY REGION, 2024–2031 (USD MILLION) 165.
TABLE 159 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165.
TABLE 160 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166.
TABLE 161 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166.
TABLE 162 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 167.
TABLE 163 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 167.
TABLE 164 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168.
TABLE 165 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168.
TABLE 166 CLINICAL CHEMISTRY MARKET, BY REGION, 2024–2031 (USD MILLION) 169.
TABLE 167 NORTH AMERICA: CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 169.
TABLE 168 EUROPE: CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170.
TABLE 169 ASIA PACIFIC: CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170.
TABLE 170 HEMATOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 171.
TABLE 171 NORTH AMERICA: HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171.
TABLE 172 EUROPE: HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172.
TABLE 173 ASIA PACIFIC: HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172.
TABLE 174 MICROBIOLOGY & CULTURE MARKET, BY REGION, 2024–2031 (USD MILLION) 173.
TABLE 175 NORTH AMERICA: MICROBIOLOGY & CULTURE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 173.
TABLE 176 EUROPE: MICROBIOLOGY & CULTURE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174.
TABLE 177 ASIA PACIFIC: MICROBIOLOGY & CULTURE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174.
TABLE 178 COAGULATION TESTING MARKET, BY REGION, 2024–2031 (USD MILLION) 175.
TABLE 179 NORTH AMERICA: COAGULATION TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175.
TABLE 180 EUROPE: COAGULATION TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176.
TABLE 181 ASIA PACIFIC: COAGULATION TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176.
TABLE 182 FLOW CYTOMETRY MARKET, BY REGION, 2024–2031 (USD MILLION) 177.
TABLE 183 NORTH AMERICA: FLOW CYTOMETRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177.
TABLE 184 EUROPE: FLOW CYTOMETRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178.
TABLE 185 ASIA PACIFIC: FLOW CYTOMETRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178.
TABLE 186 OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 179.
TABLE 187 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179.
TABLE 188 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180.
TABLE 189 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180.
TABLE 190 IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 182.
TABLE 191 IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 183.
TABLE 192 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 183.
TABLE 193 EUROPE: IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 184.
TABLE 194 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 184.
TABLE 195 IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY REGION, 2024–2031 (USD MILLION) 185.
TABLE 196 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 185.
TABLE 197 EUROPE: IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 186.
TABLE 198 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 186.
TABLE 199 IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY REGION, 2024–2031 (USD MILLION) 187.
TABLE 200 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 187.
TABLE 201 EUROPE: IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 188.
TABLE 202 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 188.
TABLE 203 IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY REGION, 2024–2031 (USD MILLION) 189.
TABLE 204 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 189.
TABLE 205 EUROPE: IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 190.
TABLE 206 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 190.
TABLE 207 IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2024–2031 (USD MILLION) 191.
TABLE 208 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 191.
TABLE 209 EUROPE: IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 192.
TABLE 210 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 192.
TABLE 211 IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY REGION, 2024–2031 (USD MILLION) 193.
TABLE 212 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 193.
TABLE 213 EUROPE: IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 194.
TABLE 214 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 194.
TABLE 215 IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY REGION, 2024–2031 (USD MILLION) 195.
TABLE 216 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY COUNTRY, 2024–2031 (USD MILLION) 195.
TABLE 217 EUROPE: IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY COUNTRY, 2024–2031 (USD MILLION) 196.
TABLE 218 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY COUNTRY, 2024–2031 (USD MILLION) 196.
TABLE 219 IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY REGION, 2024–2031 (USD MILLION) 197.
TABLE 220 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 197.
TABLE 221 EUROPE: IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 198.
TABLE 222 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 198.
TABLE 223 IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 199.
TABLE 224 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 199.
TABLE 225 EUROPE: IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 200.
TABLE 226 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 200.
TABLE 227 IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 202.
TABLE 228 IN-HOUSE MANUFACTURING MARKET, BY REGION, 2024–2031 (USD MILLION) 203.
TABLE 229 NORTH AMERICA: IN-HOUSE MANUFACTURING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 203.
TABLE 230 EUROPE: IN-HOUSE MANUFACTURING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 203.
TABLE 231 ASIA PACIFIC: IN-HOUSE MANUFACTURING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 204.
TABLE 232 THIRD-PARTY SUPPLY MARKET, BY REGION, 2024–2031 (USD MILLION) 205.
TABLE 233 NORTH AMERICA: THIRD-PARTY SUPPLY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205.
TABLE 234 EUROPE: THIRD-PARTY SUPPLY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205.
TABLE 235 ASIA PACIFIC: THIRD-PARTY SUPPLY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 236 IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 208.
TABLE 237 BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 209.
TABLE 238 BIOLOGICAL/NATURAL SOURCES MARKET, BY REGION, 2024–2031 (USD MILLION) 209.
TABLE 239 NORTH AMERICA: BIOLOGICAL/NATURAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 209.
TABLE 240 EUROPE: BIOLOGICAL/NATURAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 210.
TABLE 241 ASIA PACIFIC: BIOLOGICAL/NATURAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 210.
TABLE 242 ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION) 211.
TABLE 243 NORTH AMERICA: ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 211.
TABLE 244 EUROPE: ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212.
TABLE 245 ASIA PACIFIC: ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212.
TABLE 246 HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION) 213.
TABLE 247 NORTH AMERICA: HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213.
TABLE 248 EUROPE: HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214.
TABLE 249 ASIA PACIFIC: HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214.
TABLE 250 RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 215.
TABLE 251 RECOMBINANT/SYNTHETIC SOURCES MARKET, BY REGION, 2024–2031 (USD MILLION) 215.
TABLE 252 NORTH AMERICA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216.
TABLE 253 EUROPE: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216.
TABLE 254 ASIA PACIFIC: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216.
TABLE 255 E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION) 217.
TABLE 256 NORTH AMERICA: E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218.
TABLE 257 EUROPE: E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218.
TABLE 258 ASIA PACIFIC: E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218.
TABLE 259 CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION) 219.
TABLE 260 NORTH AMERICA: CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 220.
TABLE 261 EUROPE: CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 220.
TABLE 262 ASIA PACIFIC: CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 220.
TABLE 263 CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION) 221.
TABLE 264 NORTH AMERICA: CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 222.
TABLE 265 EUROPE: CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 222.
TABLE 266 ASIA PACIFIC: CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 222.
TABLE 267 OTHER IVD RAW MATERIAL SOURCES MARKET, BY REGION, 2024–2031 (USD MILLION) 223.
TABLE 268 NORTH AMERICA: OTHER IVD RAW MATERIAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223.
TABLE 269 EUROPE: OTHER IVD RAW MATERIAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224.
TABLE 270 ASIA PACIFIC: IVD RAW MATERIAL OTHER SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224.
TABLE 271 IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 226.
TABLE 272 IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY REGION, 2024–2031 (USD MILLION) 227.
TABLE 273 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY COUNTRY, 2024–2031 (USD MILLION) 227.
TABLE 274 EUROPE: IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY COUNTRY, 2024–2031 (USD MILLION) 228.
TABLE 275 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY COUNTRY, 2024–2031 (USD MILLION) 228.
TABLE 276 IVD RAW MATERIALS MARKET FOR CROS, BY REGION, 2024–2031 (USD MILLION) 229.
TABLE 277 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR CROS, BY COUNTRY, 2024–2031 (USD MILLION) 229.
TABLE 278 EUROPE: IVD RAW MATERIALS MARKET FOR CROS, BY COUNTRY, 2024–2031 (USD MILLION) 230.
TABLE 279 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR CROS, BY COUNTRY, 2024–2031 (USD MILLION) 230.
TABLE 280 IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 231.
TABLE 281 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 231.
TABLE 282 EUROPE: IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 232.
TABLE 283 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 232.
TABLE 284 IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 233.
TABLE 285 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 233.
TABLE 286 EUROPE: IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 234.
TABLE 287 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 234.
TABLE 288 IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 235.
TABLE 289 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 235.
TABLE 290 EUROPE: IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 236.
TABLE 291 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 236.
TABLE 292 IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION) 238.
TABLE 293 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 240.
TABLE 294 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 241.
TABLE 295 NORTH AMERICA: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 241.
TABLE 296 NORTH AMERICA: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 242.
TABLE 297 NORTH AMERICA: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 242.
TABLE 298 NORTH AMERICA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 242.
TABLE 299 NORTH AMERICA: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 243.
TABLE 300 NORTH AMERICA: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 243.
TABLE 301 NORTH AMERICA: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 243.
TABLE 302 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 244.
TABLE 303 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 244.
TABLE 304 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 245.
TABLE 305 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 245.
TABLE 306 NORTH AMERICA: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 245.
TABLE 307 NORTH AMERICA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 246.
TABLE 308 US: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 247.
TABLE 309 US: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 247.
TABLE 310 US: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 248.
TABLE 311 US: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 248.
TABLE 312 US: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 248.
TABLE 313 US: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 249.
TABLE 314 US: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 249.
TABLE 315 US: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 249.
TABLE 316 US: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 250.
TABLE 317 US: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 250.
TABLE 318 US: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 251.
TABLE 319 US: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 251.
TABLE 320 US: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 251.
TABLE 321 US: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 252.
TABLE 322 US: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 252.
TABLE 323 CANADA: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 253.
TABLE 324 CANADA: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 254.
TABLE 325 CANADA: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 254.
TABLE 326 CANADA: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 254.
TABLE 327 CANADA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 255.
TABLE 328 CANADA: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 255.
TABLE 329 CANADA: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 255.
TABLE 330 CANADA: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 256.
TABLE 331 CANADA: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 256.
TABLE 332 CANADA: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 257.
TABLE 333 CANADA: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 257.
TABLE 334 CANADA: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 258.
TABLE 335 CANADA: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 258.
TABLE 336 CANADA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 258.
TABLE 337 CANADA: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 259.
TABLE 338 EUROPE: IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 260.
TABLE 339 EUROPE: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 261.
TABLE 340 EUROPE: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 261.
TABLE 341 EUROPE: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 262.
TABLE 342 EUROPE: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 262.
TABLE 343 EUROPE: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 262.
TABLE 344 EUROPE: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 263.
TABLE 345 EUROPE: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 263.
TABLE 346 EUROPE: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 263.
TABLE 347 EUROPE: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 264.
TABLE 348 EUROPE: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 264.
TABLE 349 EUROPE: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 265.
TABLE 350 EUROPE: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 265.
TABLE 351 EUROPE: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 265.
TABLE 352 EU